Lipocine Inc. (LPCN)
NASDAQ: LPCN · Real-Time Price · USD
4.437
+0.187 (4.40%)
Oct 3, 2024, 12:49 PM EDT - Market open

Company Description

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders.

Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.

The company’s pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor.

It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth.

The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

Lipocine Inc.
Lipocine logo
Country United States
Founded 1997
Industry Biotechnology
Sector Healthcare
Employees 17
CEO Mahesh Patel

Contact Details

Address:
675 Arapeen Drive, Suite 202
Salt Lake City, Utah 84108
United States
Phone 801 994 7383
Website lipocine.com

Stock Details

Ticker Symbol LPCN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001535955
CUSIP Number 53630X104
ISIN Number US53630X2036
Employer ID 99-0370688
SIC Code 2834

Key Executives

Name Position
Dr. Mahesh V. Patel Ph.D. Co-Founder, Interim Principal Financial Officer, Director, President and Chief Executive Officer
Krista Fogarty Principal Accounting Officer and Corporate Controller
Dr. Nachiappan Chidambaram Ph.D. Senior Vice President of Research and Development
Logan Morse Vice President of Sales, Marketing and Operations
Dr. Anthony DelConte M. D., M.D. Chief Medical Director

Latest SEC Filings

Date Type Title
Oct 2, 2024 8-K Current Report
Sep 30, 2024 8-K Current Report
Sep 5, 2024 8-K Current Report
Aug 27, 2024 8-K Current Report
Aug 8, 2024 8-K Current Report
Aug 8, 2024 10-Q Quarterly Report
Aug 7, 2024 8-K/A [Amend] Current report
Jun 25, 2024 8-K Current Report
Jun 10, 2024 8-K Current Report
Jun 5, 2024 8-K Current Report